Nereus Pharmaceuticals is an innovative drug discovery and development company based in San Diego. They specialize in using marine microbiology technologies to identify and synthesize biologically active compounds. Currently, they have two oncology drug candidates in Phase I clinical trials: Plinabulin (NPI-2358), a tumor vascular disrupting agent for solid tumors, and NPI-0052, a proteasome inhibitor for solid tumors, lymphomas, and multiple myeloma. In addition to oncology, Nereus Pharmaceuticals also has drug candidates for infectious diseases and inflammation. Founded in 1998, the company is focused on tapping into untapped sources of chemical diversity.